Access the full text.
Sign up today, get DeepDyve free for 14 days.
Sung-Won Kim, S. Yoon, R. Suzuki, H. Yi, Hiroatsu Ago, M. Imamura, A. Wake, Takashi Yoshida, Je-Jung Lee, Jin Kim, Y. Maeda, K. Izutsu, H. Kang, Je-Hwan Lee, H. Kim, J. Suzumiya, Y. Matsuno, Chul Kim, K. Nagafuji, Y. Takaue, M. Harada, Chul Kim (2009)
Autologous Versus Allogeneic Hematopoietic Stem Cell Transplantation (SCT) for Peripheral T-Cell Lymphomas (PTCLs): Japan and Korea Cooperative Study with 330 Patients.Blood, 114
M. Pfreundschuh, L. Trümper, M. Kloess, R. Schmits, A. Feller, C. Rübe, C. Rudolph, M. Reiser, D. Hossfeld, H. Eimermacher, D. Hasenclever, N. Schmitz, M. Loeffler (2004)
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.Blood, 104 3
N. Fowler, B. Kahl, P. Rosen, J. Matous, A. Cashen, S. Jacobs, J. Letzer, B. Amin, Michael Williams, M. Ross, Sonali Smith, A. Saleh, Hongliang Shi, S. Parasuraman, B. Cheson (2009)
Bortezomib, Bendamustine, and Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma: Encouraging Activity in the Phase 2 VERTICAL Study.Blood, 114
Fulya Ozpuyan, Paul Meyer, H. Ni, H. Al‐Masri, S. Alkan (2007)
Bortezomib induces apoptosis in T-cell prolymphocytic leukemia (T-PLL)Leukemia & Lymphoma, 48
R. Piekarz, J. Wright, R. Frye, S. Allen, D. Joske, M. Kirschbaum, I. Lewis, M. Prince, Sonali Smith, E. Jaffe, S. Bates (2008)
Final Results of a Phase 2 NCI Multicenter Study of Romidepsin in Patients with Relapsed Peripheral T-Cell Lymphoma (PTCL).Blood, 114
M. Sieniawski, James Lennard, Christopher Millar, S. Lyons, P. Mounter, Z. Maung, S. Proctor, A. Lennard (2009)
Aggressive Primary Chemotherapy Plus Autologous Stem Cell Transplantation Improves Outcome for Peripheral T Cell Lymphomas Compared with CHOP-Like Regimens.Blood, 114
M. Dimopoulos, R. García-Sanz, M. Gavriatopoulou, P. Morel, M. Kyrtsonis, E. Katodritou, E. Michalis, Z. Kartasis, X. Leleu, G. Palladini, A. Tedeschi, D. Gika, E. Terpos, G. Merlini, E. Kastritis, P. Sonneveld (2009)
Primary Therapy of Waldenström's Macroglobulinemia (WM) with Weekly Bortezomib, Low-Dose Dexamethasone and Rituximab (BDR): A Phase II Study of the European Myeloma NetworkBlood, 114
J. Vose, J. Armitage, D. Weisenburger (2008)
International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 25
M. Duvic, Youn Kim, T. Kuzel, T. Pacheco, F. Foss, S. Parker, S. Rizvi, Cong Chen, J. Arduino, E. Olsen (2009)
The Systemic Effects of Vorinostat in Patients (Pts) with Cutaneous T-Cell Lymphoma (CTCL): Post-Hoc Analyses in Pts with High Blood Tumor Burden.Blood, 114
P. Reimer, T. Rüdiger, E. Geissinger, F. Weissinger, C. Nerl, N. Schmitz, A. Engert, H. Einsele, H. Müller-hermelink, M. Wilhelm (2009)
Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 1
O. O’Connor, S. Horwitz, P. Hamlin, C. Portlock, C. Moskowitz, D. Sarasohn, E. Neylon, Jill Mastrella, Rachel Hamelers, Barbara Macgregor-Cortelli, M. Patterson, V. Seshan, F. Sirotnak, M. Fleisher, D. Mould, M. Saunders, A. Zelenetz (2009)
Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 26
D. Buglio, G. Georgakis, S. Hanabuchi, K. Arima, N. Khaskhely, Yong‐jun Liu, A. Younes (2008)
Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines.Blood, 112 4
B. Pohlman, R. Advani, M. Duvic, K. Hymes, T. Intragumtornchai, A. Lekhakula, O. Shpilberg, A. Lerner, D. Ben-yehuda, M. Beylot‐Barry, U. Hillen, J. Fagerberg, F. Foss (2009)
Final Results of a Phase II Trial of Belinostat (PXD101) in Patients with Recurrent or Refractory Peripheral or Cutaneous T-Cell Lymphoma.Blood, 114
L. Pinter-Brown, S. Horwitz, B. Pro, P. Zinzani, C. Gisselbrecht, B. Cortelli, S. Fruchtman, O. O’Connor (2009)
Safety and Management of Pralatrexate Treatment in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL).Blood, 114
E. Carcereny, S. Castellví-Bel, V. Alonso, X. García-Albéniz, J. Muñoz, R. Gallego, C. Hondler, A. Castells, P. Gascón, J. Maurel (2008)
EGFR polymorphisms as predictors of clinical outcome in patients with advanced colorectal cancer (ACRC) treated with cetuximab and panitumumabJournal of Clinical Oncology, 26
F. d'Amore, T. Relander, G. Lauritzsen, E. Jantunen, H. Hagberg, H. Anderson, E. Cavallin-ståhl, H. Holte, Anders Østerborg, M. Merup, M. Hansen, R. Telhaug, M. Erlanson, O. Kuittinen, O. Gadeberg, J. Delabie, C. Sundström, E. Ralfkiær, M. Vornanen, C. Jensen (2006)
Dose-Dense Induction Followed by Autologous Stem Cell Transplant (ASCT) as 1st Line Treatment in Peripheral T-Cell Lymphomas (PTCL) - A Phase II Study of the Nordic Lymphoma Group (NLG).Blood, 108
M Pfreundschuh, L Trümper, M Kloess (2004)
German High-Grade non-Hodgkin's Lymphoma Study Group (DSHNHL) two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHLBlood, 104
R. Advani, F. Hong, K. Ganjoo, J. Manola, L. Swinnen, T. Habermann, S. Horning (2009)
Cardiac Toxicity Associated with the Anti-VEGF Monoclonal Antibody Bevacizumab (Avastin) in Combination with CHOP (A-CHOP) Chemotherapy for Peripheral T Cell Lymphoma (PTCL): The ECOG 2404 Trial.Blood, 114
A. Gallamini, C. Stelitano, R. Calvi, M. Bellei, D. Mattei, U. Vitolo, F. Morabito, M. Martelli, E. Brusamolino, E. Iannitto, F. Zaja, S. Cortelazzo, L. Rigacci, L. Devizzi, G. Todeschini, G. Santini, M. Brugiatelli, M. Federico (2004)
Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study.Blood, 103 7
S Swerdlow, E Campo, N Harris (2008)
Tumours of hematopoietic and lymphoid tissues
Peripheral T-cell lymphomas (PTCL) comprise a heterogeneous group of lymphatic neoplasms, which originate from mature (post-thymic) T-cells. Although comprising less than 15% of all non-Hodgkin lymphomas (NHL) in adults in Western countries, T-cell lymphomas still pose a considerable clinical challenge. To date, no standard therapy is available for the treatment of these T-cell malignancies. Treatment options that brought about substantial clinical progress in B-cell lymphomas perform only very poorly when used for T-cell lymphomas. With standard chemotherapy such as CHOP approximately 30% of T-cell lymphomas show a primary refractory course and only 35% of patients survive after 3–5 years. Therefore, novel treatment approaches need to be designed and validated in clinical trials. Here we discuss recent data including those presented at the last annual meeting of the American Society of Haematology (ASH 2009). Currently under investigation are new treatment modalities such as immune modulatory drugs, antifolates or histone deacetylase inhibitors. In addition, we present the ongoing trials that incorporate these new modalities.
memo - Magazine of European Medical Oncology – Springer Journals
Published: Jun 18, 2010
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.